RESULTS: A total of 538 patients were retained for analysis (mean age and proteinuria respectively 39 years and 1.1g/day). The distribution of variables is heterogenous: 205 patients were M0S0E0T0C0 (38%), 105 with S1 alone (19.5%), 34 were S1 and T1 (9.5%), 25 with S1 and E1 (4.6%), 22 were only M1 (4%), 21 patients M1 and S1 (3.9%), and 15 with only E1 (2.8%). M0S0E0T0 was set as the reference (Hazard Ratio (HR) for progression ¼1). The higher and significant risk for progression was found for the association S1T1 (HR 15.5 p<0.0001), E1 alone (HR 6.8 P¼0.0046), and S1E1 (HR 4.9 p<0.01). Isolated S1 (HR 1.25 p¼0.66), isolated M1 (HR 1.52 p¼0.7), and M1S1 (HR 2.5 p¼0.16) were not significantly associated with the GFR decline. CONCLUSIONS: This combinatory approach of Oxford classification lesions allows to identifying the most frequent histological presentations with better homogeneity in renal outcomes prediction. Isolated S1 lesion does not seem to associate with significantly poorer outcomes. difference to patient and organ survival; toxicity associated with long term treatment is recognised. Withdrawal of treatment is associated with disease relapse. It is unclear if there are cohorts of patients in whom immunosuppression can be withdrawn and if so when. We report, from our centre on the long term outcomes on 93 patients in whom steroid maintenance treatment was withdrawn after a stable remission was achieved. METHODS: 93 patients were identified from a long term cohort of 219 patients presenting over a 13 year period. Data collected from medical records. Follow-up ranged from 6 to 168 months (median 60 months). Remission was achieved with standard induction (Plasma Exchange, Cyclophosphamide (cyclo) (oral or intravenous), mycophenolate mofetil (MMF) or Rituximab; all in combination with corticosteroid) and maintained with Azathioprine or MMF in combination with corticosteroid. In patients in whom a stable remission was achieved, withdrawal of corticosteroid would begin at 18 to 24 months. We have looked at steroid withdrawal and subsequent disease activity. RESULTS: Thirty-eight patients were female; 87 of white ethinicity; median age at diagnosis of 69 years (range 18-89). Median creatinine at presentation was 309 umol/L; 22 patients had a serum creatinine above 500 umol/L. Induction treatment: 86 patients received cyclophosphamide (6 oral, 80 IV); 1 Rituximab, 1 Azathioprine, 5 MMF. Thirty patients received plasma exchange. CONCLUSIONS: In this cohort we have so far not identified a clear predictor of steroid withdrawal without relapse, however 77% of our patients remain relapse free off steroid with significant follow up period. We would suggest that withdrawal of steroid should be the aim when patients have achieved a stable remission, and that this can be achieved safely with close monitoring. 
INTRODUCTION AND AIMS:
Current immunosuppressive regimens have made a marked difference to patient and organ survival; toxicity associated with long term treatment is recognised. Withdrawal of treatment is associated with disease relapse. It is unclear if there are cohorts of patients in whom immunosuppression can be withdrawn and if so when. We report, from our centre on the long term outcomes on 93 patients in whom steroid maintenance treatment was withdrawn after a stable remission was achieved. METHODS: 93 patients were identified from a long term cohort of 219 patients presenting over a 13 year period. Data collected from medical records. Follow-up ranged from 6 to 168 months (median 60 months). Remission was achieved with standard induction (Plasma Exchange, Cyclophosphamide (cyclo) (oral or intravenous), mycophenolate mofetil (MMF) or Rituximab; all in combination with corticosteroid) and maintained with Azathioprine or MMF in combination with corticosteroid. In patients in whom a stable remission was achieved, withdrawal of corticosteroid would begin at 18 to 24 months. We have looked at steroid withdrawal and subsequent disease activity. RESULTS: Thirty-eight patients were female; 87 of white ethinicity; median age at diagnosis of 69 years (range 18-89). Median creatinine at presentation was 309 umol/L; 22 patients had a serum creatinine above 500 umol/L. Induction treatment: 86 patients received cyclophosphamide (6 oral, 80 IV); 1 Rituximab, 1 Azathioprine, 5 MMF. Thirty patients received plasma exchange. CONCLUSIONS: In this cohort we have so far not identified a clear predictor of steroid withdrawal without relapse, however 77% of our patients remain relapse free off steroid with significant follow up period. We would suggest that withdrawal of steroid should be the aim when patients have achieved a stable remission, and that this can be achieved safely with close monitoring. 
In this retrospective, single-center study we aimed to assess long-term outcome of patients with severe ANCA-associated vasculitis (AASV) treated with Rituximab. METHODS: A total of 37 patients, 22 male and 15 female, with a mean age of 63614 years were included. All patients had biopsy-proven renal AASV with median eGFR at diagnosis 21ml/min (range 9 to 29), while 9 out of 37 (24%) were dialysis-dependent and 7 out of 37 (19%) presented with concomitant pulmonary hemorrhage. The majority (27 out of 37, 73%) were MPO positive with median MPO titer of 69 (range 9 to 482), 5 (13%) were c ANCA positive, while 5 more were ANCA negative. Median follow up was 28 months with 10 patients reaching more than 5 years of follow up. RESULTS: Induction with three different dosing regimens of Rituximab was introduced in 27 out of 37 (73%) patients. All but one patients also received low dose cyclophosphamide (median cumulative dose 3.8gr -IQR:2-6.2) and methylprednisolone. At 6 months, median eGFR increased to 35ml/min (range 15 to 53) and 4 out of 7 (57%) became dialysis independent. B-cells well depleted in all patients. Death due to infection occurred in 2 patients and 2 more were lost to follow up. Maintenance with 500mg of Rituximab every 6 months for a total of 24 months and low-dose methylprednisolone for 6 to 12 months was introduced to 8 out of 25 patients (32%) who received maintenance therapy. All were in complete remission which was sustained in 6 out of 8 (76%) patients for a median of 23 months (range 11 to 49), with median eGFR of 38ml/ min (range 15 to 52) and median proteinuria 0.2g/24hr (range 0.17 to 0.5). Two patients relapsed after 32 and 47 months respectively, the first with pulmonary hemorrhage and the second with a severe renal flare. From the total cohort, 9 out of 37 patients were treated successfully with Rituximab for a major relapse: four for a renal flare, 3 for pulmonary relapse and 2 for pulmonary hemorrhage. Both patients with pulmonary hemorrhage had also received PLEX and pulses of methylprednisolone. CONCLUSIONS: Rituximab in combination with low-dose conventional immunosuppression is effective even in patients with life-threatening organ involvement. 
FP191 TROUGH LEVEL AND DOSE PER BODY WEIGHT ARE PRACTICAL PREDICTORS OF MYCOPHENOLIC ACID EXPOSURE IN ACTIVE LUPUS NEPHRITIS
.h/L). However, measurement of MPA-AUC 0-12h is cumbersome. Hence, we compared the performance of each single time point MPA concentration and abbreviated MPA-AUC 0-2h in predicting MPA-AUC 0-12h. METHODS: Forty-four Thai patients with active LN who received a stable dose of mycophenolate mofetil (MMF) for at least 1 month were included. Total MPA plasma concentrations at pre-morning dose, and 0.5, 1, 2, 3, 4, 8, and 12 hours after the morning dose were measured by the fluorescence polarization immunoassay by COBAS INTEGRA 400/800 analyzer. MPA-AUC 0-12h was calculated using the linear trapezoidal rule. Pearson's correlation analysis was used to determine the correlation between MPA-AUC 0-12h and single time point MPA concentrations and abbreviated MPA-AUC 0-2h. Receiver operating curve (ROC) was performed to determine the best cutoff value in predicting MPA-AUC 0-12h 45 mg.h/L. RESULTS: Ninety-one percent of studied patients were female with average age of 30.4067.54 years old. Mean body weight was 56611 kg and creatinine was 0.8760.24 mg/dL. The average MMF dosage was 15956438 mg/day. Mean MPA-AUC 0-12h was 49623 mg.h/L Fifty-two percent of patients had MPA-AUC 0-12h more than 45 mg.h/ L. The coefficient of variation of dose normalized MPA-AUC 0-12h was 50%. The performance of MPA-C0 and MMF dose/body weight in differentiating high and low MPA-AUC 0-12h ( 45 mg h/L) was as good as abbreviated MPA-AUC 0-2h (ROC-AUC 0.84 and 0.80 versus 0.81-0.9)( Table 1 ). The threshold of MPA-C0 3 mg/L and MMF dosage/body weight 36 mg/kg/day provided a very high specificity for MPA-AUC 0-12h 45 mg.h/L (specificity 95% and 92%, respectively)( Table 2) . CONCLUSIONS: MPA-C0 of 3 mg/L and MMF dosage/body weight of 36 mg/kg/ day were highly correlated with adequate MPA exposure. The targeted dose of MMF dosage/body weight of more than 36 mg/kg/day, followed by MPA-C0 monitoring to achieve a level of more than 3 mg/L could be a practical tool to ensure adequate MPA exposure in active LN. (TWEAK) is a member of the tumor necrosis factor superfamily, a type II transmembrane protein that circulates in the plasma in a cleaved soluble form. Serum TWEAK has been shown to be increased in rheumatoid arthritis patients compared to healthy controls and to correlate with disease activity. Urinary TWEAK has previously been shown to be a potential biomarker in lupus nephritis patients and TWEAK blockade decreases severity of disease in a murine experimental lupus nephritis model. Our aim was to investigate the role of serum and urinary TWEAK in patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). METHODS: Seventy-six patients (43 men, 33 women, median age 58, range 19-86) with AAV (66 new diagnosis, 10 relapses) were included in the study and followed up for 6 months (summary of patient characteristics in table 1). Disease activity was assessed using the Birmingham Vasculitis Score 2003 (BVAS) at baseline and at followup. Serum and urinary TWEAK was measured with a commercially available ELISA kit from Bioscience (Hatfield, UK) as well as CRP and Creatinine at baseline and at 6 months. For comparison serum TWEAK was measured in 20 randomly selected controls from a population-based cohort. RESULTS: Serum TWEAK did not change significantly between 0 and 6 months and there was no difference between levels in AAV patients and controls (mean TWEAK 538.0 pg/ml, 497.4 and 522,5 pg/ml respectively). CRP and BVAS decreased significantly but not creatinine. Urinary TWEAK/creatinine ratio decreased significantly in patients at the 6 months follow-up compared to at baseline (P <0.001), mean 9.5 pg/ mmol and 5.5 pg/mmol at baseline and 6 months respectively. Furthermore, we found a correlation between urinary TWEAK/creatinine and disease activity (BVAS) at baseline (&#961; 0.35, P 0.0024) but not at follow-up. CONCLUSIONS: Our results suggest that urinary TWEAK/creatinine ratio may be useful as a biomarker that reflects disease activity in AAV patients whereas serum TWEAK does not. Future studies may delineate the possible role of TWEAK in the pathogenesis and treatment of AAV. We aim to investigate the role of TWEAK and its receptor Fn14 further by assessing the expression of TWEAK/Fn14 in renal tissue from patients with AAV by histopathological staining. 
